I

Isu Abxis Co Ltd
KOSDAQ:086890

Watchlist Manager
Isu Abxis Co Ltd
KOSDAQ:086890
Watchlist
Price: 5 970 KRW -1.16% Market Closed
Market Cap: ₩236.9B

Net Margin

42.4%
Current
Improving
by 35.2%
vs 3-y average of 7.1%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
42.4%
=
Net Income
₩28.1B
/
Revenue
₩66.4B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
42.4%
=
Net Income
₩28.1B
/
Revenue
₩66.4B

Peer Comparison

Country Company Market Cap Net
Margin
KR
Isu Abxis Co Ltd
KOSDAQ:086890
236.8B KRW
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
393.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
172.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.5B USD
Loading...
AU
CSL Ltd
ASX:CSL
88.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.4B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Higher than 97% of companies in Korea
Percentile
97th
Based on 2 632 companies
97th percentile
42.4%
Low
-168 471.3% — -2.9%
Typical Range
-2.9% — 5.8%
High
5.8% — 21 012.5%
Distribution Statistics
Korea
Min -168 471.3%
30th Percentile -2.9%
Median 1.9%
70th Percentile 5.8%
Max 21 012.5%

Isu Abxis Co Ltd
Glance View

Market Cap
236.9B KRW
Industry
Biotechnology

ISU Abxis Co., Ltd. engages in the provision of pharmaceutical products. The company is headquartered in Seongnam, Gyeonggi-Do and currently employs 143 full-time employees. The company went IPO on 2009-02-03. The firm operates its business under two divisions: antibody therapeutics business division and diagnostic business division. Its antibody therapeutics business division engages in the development of Cloticab, which is a monoclonal therapeutic antibody for thrombus. Its diagnostic business division engages in the provision of genetic testing services and chemotherapy response assay services for cancer examination.

Intrinsic Value
9 348.74 KRW
Undervaluation 36%
Intrinsic Value
Price
I
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
42.4%
=
Net Income
₩28.1B
/
Revenue
₩66.4B
What is Isu Abxis Co Ltd's current Net Margin?

The current Net Margin for Isu Abxis Co Ltd is 42.4%, which is above its 3-year median of 7.1%.

How has Net Margin changed over time?

Over the last 3 years, Isu Abxis Co Ltd’s Net Margin has increased from 0.8% to 42.4%. During this period, it reached a low of -17.6% on Dec 31, 2022 and a high of 49.7% on Jun 30, 2025.

Back to Top